STAT3 and myelofibrosis: We show that this persistent STAT3 phosphorylation and activation in the injured muscle is an important driver of NHO as administration of ruxolitinib, a small synthetic inhibitor of JAK1/2 tyrosine kinases used to treat myelofibrosis and polycythemia vera caused by activating mutations of JAK2 (27, 28), significantly reduced STAT3 phosphorylation in the injured muscles of mice.